Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Fig. 4

Elevated S100A8/A9 serum levels are associated with impaired overall survival in melanoma patients. Kaplan-Meier survival curves for overall survival stratified by normal (≤5.5 mg/l) or elevated (> 5.5 mg/l) S100A8/A9 serum levels. a Depicts the training set (n = 114), b the independent validation set (n = 240). Hazard ratios were calculated using univariate Cox regression. Numbers in brackets indicate 95% confidence intervals. P-values were calculated using two-sided Log-Rank test. Abbreviations: HR = hazard ratio, P = P-value

Back to article page